Merck News Item

Healthcare Professionals - Opens new window


		Contact Newsroom
		Podcast
		RSS

These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.

28 Apr 2008	Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)

25 Apr 2008	Schering-Plough/Merck Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast

24 Apr 2008	Two Merck Medicines Recommended for Approval in the European Union

17 Apr 2008	Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV™

01 Apr 2008	Merck's Investigational Rolofylline Associated with Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study

31 Mar 2008	Update on ACHIEVE: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™)

31 Mar 2008	Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss

31 Mar 2008	Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Reported Significantly Less Flushing Than Patients Treated with Niaspan™ in Phase III Study

17 Mar 2008	Merck Scientists Apply Innovative Research Method to Identify Changes in Gene Networks Linked to Obesity Studies Published in Nature

17 Mar 2008	Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV

13 Nov 2007	STEP Study Volunteers to be Informed Whether They Received Vaccine or Placebo

07 Nov 2007	Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective

06 Nov 2007	GTx, Inc. and Merck & Co., Inc. Enter Global Strategic Collaboration for the Development of SARMs, a Novel Investigational Class of Drugs to Treat Muscle Loss and other Musculoskeletal Conditions

05 Nov 2007	Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III Study

01 Nov 2007	Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV™, an Investigational Hepatitis B Vaccine Currently in Phase 3

top

Printer Friendly Page